07:00 , Jun 8, 2009 |  BC Week In Review  |  Company News

Xanodyne Pharmaceuticals management update

Xanodyne Pharmaceuticals Inc. , Newport, Ky.   Business: Genitourinary, Neurology, Hematology   Hired: Michael Valentino as president and CEO while remaining a director, formerly president and CEO of Adams Respiratory Therapeutics Inc. (now part of...
02:35 , Jun 5, 2009 |  BC Extra  |  Financial News

Xanodyne raises $38M, names Valentino CEO

Xanodyne Pharmaceuticals Inc. (Newport, Ky.) raised $38 million in a private round led by MPM Capital. AIG Investments; Aisling Capital; Blue Chip Venture; Essex Woodlands; HealthCare Ventures; and Union Springs also participated. All are existing...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

MiddleBrook management update

MiddleBrook Pharmaceuticals Inc. (NASDAQ:MBRK), Germantown, Md.   Business: Infectious   Hired: Frank Koos as SVP of sales and business development, formerly VP of professional sales at Adams Respiratory Therapeutics Inc. , now a subsidiary of...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Company News

MiddleBrook management update

MiddleBrook Pharmaceuticals Inc. (NASDAQ:MBRK), Germantown, Md.   Business: Infectious   Hiring: John Thievon as president, CEO and a director, formerly EVP of sales and corporate accounts at Adams Respiratory Therapeutics Inc. , which is now...
07:00 , Jul 7, 2008 |  BioCentury  |  Finance

Ebb & Flow

Fewer than one-fifth of the 660 or so VCs queried by the...
00:59 , Jul 3, 2008 |  BC Extra  |  Financial News

MiddleBrook falls on financing plans

MiddleBrook (NASDAQ:MBRK) fell $1.55 (50%) to $1.52 on Wednesday after announcing an agreement with Equity Group Investments (EGI) to raise $100 million. EGI will purchase 30.3 million shares at $3.30, which is a 7% premium...
08:00 , Feb 4, 2008 |  BC Week In Review  |  Company News

Adams Respiratory, Reckitt Benckiser plc deal

Reckitt Benckiser completed its previously announced acquisition of Adams Respiratory for $60 per share, or about $2.3 billion in cash (see BioCentury, Dec. 17, 2007). Adams Respiratory Therapeutics Inc. (NASDAQ:ARXT), Chester, N.J.   Reckitt Benckiser...
08:00 , Dec 17, 2007 |  BC Week In Review  |  Company News

Adams Respiratory, Reckitt Benckiser plc deal

Adams Respiratory Therapeutics Inc. (ARXT), Chester, N.J.   Reckitt Benckiser plc (LSE:RB), Slough, U.K.   Business: Infectious, Pulmonary   RB will acquire ARXT for $60 per share, or about $2.3 billion in cash. The price...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Clinical News

Mucinex with Codeine regulatory update

FDA issued an approvable letter in response to ARXT's NDA for Mucinex with Codeine to treat cough associated with the common cold, inhaled irritants and stable chronic bronchitis. In addition to undisclosed comments on labeling,...
07:00 , Oct 1, 2007 |  BioCentury  |  Finance

4Q milestones

4Q milestones...